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Summary
Background Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic 
stroke, and the need for coronary revascularisation in people without kidney disease, but its eﬀ ects in people with 
moderate-to-severe kidney disease are uncertain. The SHARP trial aimed to assess the eﬃ  cacy and safety of the 
combination of simvastatin plus ezetimibe in such patients. 
Methods This randomised double-blind trial included 9270 patients with chronic kidney disease (3023 on dialysis and 
6247 not) with no known history of myocardial infarction or coronary revascularisation. Patients were randomly 
assigned to simvastatin 20 mg plus ezetimibe 10 mg daily versus matching placebo. The key prespeciﬁ ed outcome was 
ﬁ rst major atherosclerotic event (non-fatal myocardial infarction or coronary death, non-haemorrhagic stroke, or any 
arterial revascularisation procedure). All analyses were by intention to treat. This trial is registered at ClinicalTrials.gov, 
NCT00125593, and ISRCTN54137607.
Findings 4650 patients were assigned to receive simvastatin plus ezetimibe and 4620 to placebo. Allocation to simvastatin 
plus ezetimibe yielded an average LDL cholesterol diﬀ erence of 0·85 mmol/L (SE 0·02; with about two-thirds 
compliance) during a median follow-up of 4·9 years and produced a 17% proportional reduction in major atherosclerotic 
events (526 [11·3%] simvastatin plus ezetimibe vs 619 [13·4%] placebo; rate ratio [RR] 0·83, 95% CI 0·74–0·94; log-rank 
p=0·0021). Non-signiﬁ cantly fewer patients allocated to simvastatin plus ezetimibe had a non-fatal myocardial infarction 
or died from coronary heart disease (213 [4·6%] vs 230 [5·0%]; RR 0·92, 95% CI 0·76–1·11; p=0·37) and there were 
signiﬁ cant reductions in non-haemorrhagic stroke (131 [2·8%] vs 174 [3·8%]; RR 0·75, 95% CI 0·60–0·94; p=0·01) and 
arterial revascularisation procedures (284 [6·1%] vs 352 [7·6%]; RR 0·79, 95% CI 0·68–0·93; p=0·0036). After weighting 
for subgroup-speciﬁ c reductions in LDL cholesterol, there was no good evidence that the proportional eﬀ ects on major 
atherosclerotic events diﬀ ered from the summary rate ratio in any subgroup examined, and, in particular, they were 
similar in patients on dialysis and those who were not. The excess risk of myopathy was only two per 10 000 patients per 
year of treatment with this combination (9 [0·2%] vs 5 [0·1%]). There was no evidence of excess risks of hepatitis 
(21 [0·5%] vs 18 [0·4%]), gallstones (106 [2·3%] vs 106 [2·3%]), or cancer (438 [9·4%] vs 439 [9·5%], p=0·89) and there 
was no signiﬁ cant excess of death from any non-vascular cause (668 [14·4%] vs 612 [13·2%], p=0·13).
Interpretation Reduction of LDL cholesterol with simvastatin 20 mg plus ezetimibe 10 mg daily safely reduced the 
incidence of major atherosclerotic events in a wide range of patients with advanced chronic kidney disease.
Funding Merck/Schering-Plough Pharmaceuticals; Australian National Health and Medical Research Council; British 
Heart Foundation; UK Medical Research Council.
Introduction
Chronic kidney disease is associated with an increased 
risk of cardiovascular disease,1,2 but little is known about 
the prevention of cardiovascular disease in patients with 
chronic kidney disease.3 Meta-analyses of randomised 
trials undertaken mainly in patients without chronic 
kidney disease have shown that statin therapy reduces the 
risks of major coronary events (myocardial infarction or 
death from coronary heart disease), ischaemic strokes, 
and coronary revascularisations by about one ﬁ fth for each 
1 mmol/L reduction in LDL cholesterol, while producing 
little eﬀ ect on haemorrhagic strokes or vascular causes of 
death other than coronary heart disease.4,5 In people with 
an estimated glomerular ﬁ ltration rate (eGFR) greater 
than 60 mL/min per 1·73 m², in whom the cause of 
cardiovascular disease is typically atherosclerotic, the 
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proportional eﬀ ects of statin therapy on vascular events 
seem to be independent of renal function.5,6 But, when 
eGFR falls below about 30 mL/min per 1·73 m², a diﬀ erent 
cardiovascular pathology emerges, with vascular stiﬀ ness 
and calciﬁ cation, structural heart disease, and sympathetic 
overactivity contributing to an increasing risk of cardiac 
arrhythmia and heart failure.2 A key question, therefore, 
is whether LDL-cholesterol-lowering therapy remains 
eﬀ ective as renal impairment progresses. 
The SHARP (Study of Heart and Renal Protection) trial 
aimed to assess the safety and eﬃ  cacy of reducing LDL 
cholesterol in more than 9000 patients with chronic 
kidney disease. To achieve an average reduction in LDL 
cholesterol of about 1 mmol/L without the use of high 
statin doses (which are associated with an increased risk 
of myopathy,7 especially in patients with impaired renal 
function8), a low dose of a statin (simvastatin 20 mg daily) 
was combined with a cholesterol-absorption inhibitor9 
(ezetimibe 10 mg daily). The biochemical eﬃ  cacy and 
tolerability of this regimen was ﬁ rst conﬁ rmed in the 
UK-HARP pilot studies.10,11 
Methods
Trial design and participants
Details of the SHARP trial objectives, design, and methods 
have been reported previously.12 Patients aged 40 years and 
older were eligible to participate if they had chronic kidney 
disease with more than one previous measurement of 
serum or plasma creatinine of at least 150 μmol/L 
(1·7 mg/dL) in men or 130 μmol/L (1·5 mg/dL) in women, 
whether receiving dialysis or not. Potentially eligible 
patients attended a screening visit at which medical history 
and other eligibility criteria were checked, written 
informed consent obtained, and non-fasting blood 
samples taken for local laboratory assays. Single-blind 
study placebo tablets were provided for a 6-week run-in 
period to identify potential non-compliers who could be 
excluded before randomisation, with a consequent 
improvement in statistical sensitivity.13 Ethical approval 
was obtained from all study sites prior to enrolment.
Randomisation and masking
At the end of the run-in period, patients who agreed to 
continue were allocated the study treatment by the local 
study laptop computer with minimised randomisation14 
(which balanced for age, sex, ethnic origin, dialysis vs 
non-dialysis, prior vascular disease, previous diabetes, 
systolic blood pressure, creatinine, and total cholesterol). 
Patients entering SHARP were initially randomised three 
ways between simvastatin 20 mg plus ezetimibe 10 mg 
daily, simvastatin 20 mg daily, and placebo to assess the 
safety of adding ezetimibe to simvastatin during the ﬁ rst 
year (with no safety concerns identiﬁ ed12) and those 
initially allocated simvastatin alone were then 
rerandomised to simvastatin 20 mg plus ezetimibe 10 mg 
daily versus placebo after 1 year (ﬁ gure 1). A double-
dummy method ensured that patients and study staﬀ  
were unaware of the treatment allocation, with all patients 
taking two tablets during the ﬁ rst year (an active 
simvastatin plus ezetimibe tablet with a placebo 
simvastatin tablet; a placebo simvastatin plus ezetimibe 
tablet with an active simvastatin tablet; or a placebo 
simvastatin plus ezetimibe tablet with a placebo 
simvastatin tablet) and, after the ﬁ rst year, one tablet 
(active or placebo simvastatin plus ezetimibe).
Procedures 
After randomisation between August, 2003, and August, 
2006, participants were to be seen in the study clinics 
for routine follow-up checks and blood safety monitoring 
at 2, 6, and 12 months, and then every 6 months for at 
least 4 years in total, until the ﬁ nal follow-up visits 
between March and August, 2010. An early recall visit 
could also be arranged for any participant requiring 
Figure 1: Trial proﬁ le 
11 792 patients attended
screening
428 not eligible or
refused
1678 not eligible or
withdrew
248 not eligible or
withdrew
168 not rerandomised
11 364 entered
run-in phase
9686 attended
randomisation
visit
9438 randomised
4193 initially assigned
simvastatin 20 mg 
plus ezetimibe 10 mg
1054 initially assigned
simvastatin 20 mg
886 rerandomised
after 1 year
Total: 4650 assigned
simvastatin plus 
ezetimibe
<4 years’ follow-up for:
Mortality, 70 (1·5%)
Morbidity, 101 (2·2%)
<4 years’ follow-up for:
Mortality, 68 (1·5%)
Morbidity, 103 (2·2%)
4650 analysed 4620 analysed
Total: 4620 assigned
placebo
4191 initially assigned
placebo
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additional review. At each follow-up, compliance with 
study treatment was estimated, any unexplained muscle 
pain and non-study treatment recorded, and weight and 
blood pressure measured. Samples of non-fasting blood 
were taken for local laboratory assay of creatine kinase, 
liver transaminase, and creatinine. Central laboratory 
assays of lipid proﬁ le were conducted at randomisation 
in samples obtained from all participants, in about 10% 
of participants attending study visits at 1 and 4 years 
after the initial randomisation, and from all participants 
attending the 2·5-year visit. Diﬀ erences between the 
treatment groups in average blood lipid concentrations 
were based on comparisons between all patients 
allocated simvastatin plus ezetimibe and all allocated 
placebo, irrespective of whether they were still compliant 
(with any missing data imputed from the initial 
randomisation values, on the basis of the assumption of 
non-compliance). 
Information was recorded at each follow-up about any 
suspected myocardial infarction, stroke, vascular 
procedure, cancer, other reasons for hospital admissions, 
or other serious adverse events. If a participant became 
unwilling or unable to attend the follow-up visits, 
information about serious adverse events was obtained 
from them (or their relative or carer) by telephone or 
from their own doctors until the scheduled end of the 
study. Local study staﬀ  then sought extra information 
from hospital records and other appropriate sources 
about all reports of serious adverse events that might 
relate to study outcomes (ie, death, myocardial infarction, 
cardiac arrest, angina, heart failure, stroke, transient 
ischaemic attack, revascularisation procedures, angio-
graphy, amputation, initiation of dialysis, kidney 
transplant, renal failure, cancer, myopathy, rhabdo-
myolysis, hepatobiliary conditions). This information 
was sent to the international coordinating centre for 
central adjudication, in accordance with prespeciﬁ ed 
deﬁ nitions, by trained clinicians who were masked to 
study treatment allocation.
Statistical analysis 
The annual incidence of major vascular events in SHARP 
(deﬁ ned as non-fatal myocardial infarction or any cardiac 
death, any stroke, or any arterial revascularisation excluding 
dialysis access procedures) was projected to be about 3·7%. 
A study with at least 1100 such events and all patients 
followed up for at least 4 years was estimated to have 
90% power to detect a 20% proportional reduction at 
p<0·01. For the reasons given in the statistical analysis 
plan published before unmasking,12 the steering committee 
decided that the key study outcome should be changed to 
major atherosclerotic events (deﬁ ned as non-fatal 
myocardial infarction or coronary death, non-haemorrhagic 
stroke, or arterial revascularisation excluding dialysis 
access procedures) and the key comparison should be 
between all patients ever allocated simvastatin plus 
ezetimibe versus placebo (including those initially allocated 
simvastatin; ﬁ gure 1). Assessments of eﬃ  cacy and safety 
were to be intention-to-treat comparisons.15,16 Time-to-event 
analyses used log-rank methods15,16 to calculate two-sided p 
values, event rate ratios, and 95% CIs. Exploratory analyses 
that made allowance for variation in the size of the LDL 
cholesterol reductions achieved within subgroups of 
patients involved rate ratios per mmol/L reduction derived 
through weighting by subgroup-speciﬁ c LDL cholesterol 
diﬀ erences at the study midpoint (2·5 years).4,5 Analyses 
were done with in-house C++ programs and veriﬁ ed with 
SAS version 9.1 and R version 2.2.1.
This study is registered at ClinicalTrials.gov, 
NCT00125593, and ISRCTN54137607.
Simvastatin plus 
ezetimibe (n=4650)
Placebo 
(n=4620)
Previous vascular disease* 711 (15%) 682 (15%)
Diabetes* 1054 (23%) 1040 (23%)
Men 2915 (63%) 2885 (62%)
Age at randomisation 
(years)*
62 (12) 62 (12)
Current smoker 626 (13%) 608 (13%)
Diastolic blood pressure 
(mm Hg)*
79 (13) 79 (13)
Systolic blood pressure 
(mm Hg)*
139 (22) 139 (22)
Total cholesterol (mmol/L) 4·88 (1·20) 4·90 (1·17)
LDL cholesterol (mmol/L) 2·77 (0·88) 2·78 (0·87)
HDL cholesterol (mmol/L) 1·12 (0·35) 1·11 (0·34)
Triglycerides (mmol/L) 2·31 (1·76) 2·34 (1·68)
Body-mass index (kg/m²)* 27·1 (5·7) 27·1 (5·6)
Renal status
On dialysis 1533 (33%) 1490 (32%)
Haemodialysis 1275 (27%) 1252 (27%)
Peritoneal dialysis 258 (6%) 238 (5%)
Not on dialysis† 3117 (67%) 3130 (68%)
MDRD-estimated GFR (mL/min per 1·73 m²)*‡§
Mean (SD) 26·6 (12·9) 26·6 (13·1)
≥60 44 (1%) 44 (1%)
≥30 to <60 1100 (37%) 1055 (35%)
≥15 to <30 1246 (41%) 1319 (44%)
<15 614 (20%) 607 (20%)
Not available 113 105
Urinary albumin:creatinine ratio (mg/g)‡§
Median (IQR) 217 (44–788) 196 (43–748)
<30 545 (20%) 562 (20%)
≥30 to ≤300 1032 (37%) 1076 (39%)
>300 1203 (43%) 1156 (41%)
Not available 337 336
Data are n (%), mean (SD), or median (IQR). MDRD=Modiﬁ ed Diet in Renal 
Disease.17 GFR=glomerular ﬁ ltration rate. *Variables updated at 1 year for patients 
originally allocated simvastatin only who were rerandomised to simvastatin plus 
ezetimibe or placebo. †Five versus ﬁ ve patients received a transplant before 
rerandomisation. ‡Percentages exclude participants for whom data were not 
available for that category. §For patients not on dialysis.
Table 1: Baseline demographic features and laboratory measurements 
by treatment allocation
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Role of the funding source
The main funding source (Merck/Schering-Plough 
Pharmaceuticals) participated in initial discussions about 
trial design, contributed two non-voting observers to the 
steering committee, and had a right to comment on (but 
not require changes to) study reports. It had no 
involvement in data collection, analysis, and inter-
pretation, report writing, or the decision to submit for 
publication, and will not receive an unmasked copy of 
the trial database. Voting members of the steering 
committee, all of whom are authors, accept full 
responsibility for the content of this paper.
Results
Overall, 9270 patients were randomly assigned to 
simvastatin plus ezetimibe (4650 patients, 4193 initially 
plus 457 after 1 year) versus placebo (4620 patients, 
4191 initially plus 429 after 1 year; ﬁ gure 1). Among these 
patients, all variables were well balanced between 
randomised groups (table 1). Mean age was 62 years 
(SD 12), 5800 (63%) were male, mean blood pressure was 
139/79 mm Hg, mean body-mass index was 
27 (SD 6) kg/m², 2094 (23%) had diabetes, and 1393 (15%) 
had a history of vascular disease (angina, stroke, or 
peripheral vascular disease). Self-reported ethnic origin 
was 6646 (72%) white, 264 (3%) black, 2086 (23%) Asian, 
and 274 (3%) other or unspeciﬁ ed. Mean baseline non-
fasting plasma concentrations were 4·9 (SD 1·2) mmol/L 
for total cholesterol, 2·8 (SD 0·9) mmol/L for directly 
measured LDL cholesterol, 1·1 (SD 0·3) mmol/L for 
HDL cholesterol, and 2·3 (SD 1·7, IQR 1·3–2·8) mmol/L 
for triglycerides (table 1).
3023 (33%) patients were receiving maintenance 
dialysis at randomisation (2527 [27%] haemodialysis and 
496 [5%] peritoneal dialysis; table 1). Mean LDL 
cholesterol concentration was lower in patients on 
dialysis than in those who were not (2·6 [SD 0·9] vs 
2·9 [SD 0·9] mmol/L; p<0·0001). Among the 6029 (97%) 
of 6247 patients not on dialysis with centrally measured 
creatinine, the average eGFR estimated with the 
Modiﬁ cation of Diet in Renal Disease equation17 was 
26·6 (SD 13·0) mL/min per 1·73 m² (table 1): 2155 (36%) 
had Kidney Disease Outcomes Quality Initiative18 stage 
3 disease (eGFR 30–59 mL/min per 1·73 m²), 2565 
(43%) stage 4 disease (eGFR 15–29 mL/min per 1·73 m²), 
and 1221 (20%) stage 5 disease (eGFR <15 mL/min per 
1·73 m²). Among the 5574 (89%) of 6247 patients not on 
dialysis with a centrally measured urinary albumin-to-
creatinine ratio (ACR), 1107 (20%) had ACR lower than 
30 mg/g, 2108 (38%) had ACR 30–300 mg/g, and 
2359 (42%) had ACR higher than 300 mg/g (table 1). 
The median duration of follow-up was 4·9 years for 
surviving patients. During the scheduled treatment 
period, slightly fewer patients allocated simvastatin plus 
ezetimibe discontinued study treatment (1533 [33·0%] 
simvastatin plus ezetimibe vs 1669 [36·1%] placebo); this 
ﬁ nding was chieﬂ y attributable to slightly more placebo-
allocated patients commencing non-study statin therapy 
(337 [9·6%] vs 513 [14·6%]; p<0·0001). Among patients 
allocated simvastatin plus ezetimibe, there were no 
signiﬁ cant excesses of discontinuations due to suspected 
serious adverse reactions (17 [0·4%] vs 12 [0·3%]), 
other serious adverse events (297 [6·4%] vs 307 [6·6%]), 
non-serious adverse events (165 [3·5%] vs 131 [2·8%]), or 
other reasons (1054 [22·7%] vs 1219 [26·4%]).
Compliance was deﬁ ned as at least 80% of the scheduled 
simvastatin plus ezetimibe or placebo tablets having 
been taken since the previous follow-up. Among the 
patients allocated simvastatin plus ezetimibe, 3403 (77%) 
of 4435 at the end of the ﬁ rst year of follow-up and 
2397 (68%) of 3512 at the end of the fourth year remained 
compliant or were taking a non-study statin and, at the 
study midpoint (2·5 years), 2864 (71%) of 4058 were 
taking simvastatin plus ezetimibe or a non-study statin 
(table 2). By contrast, in patients allocated placebo, 
124 (3%) of 4162 patients at the end of the ﬁ rst year and 
447 (14%) of 3278 at the end of the fourth year were taking 
a non-study statin and, at the study midpoint, the average 
Correspondence to:
Prof Colin Baigent, Clinical Trial 
Service Unit and Epidemiological 
Studies Unit (CTSU), Richard Doll 
Building, Old Road Campus, 
Roosevelt Drive, 
Oxford OX3 7LF, UK
sharpclinical@ctsu.ox.ac.uk 
LDL-cholesterol-lowering drug use LDL cholesterol diﬀ erence (mmol/L)*
Simvastatin 
plus ezetimibe
Placebo Absolute 
diﬀ erence
Simvastatin 
plus ezetimibe
Placebo Absolute 
diﬀ erence 
(SE)
8–13 months 77% 3% 74% –1·08 0·02 –1·09 
(0·06)
26–31 months 71% 9% 61% –1·00 –0·15 –0·85 
(0·02)
44–49 months 68% 14% 55% –0·84 –0·08 –0·77 
(0·06)
*In patients initially allocated to simvastatin, no 1-year sample was collected, while samples scheduled for collection at 
2·5 and 4 years were collected at 1·5 and 3 years after rerandomisation.
Table 2: Average use of study simvastatin plus ezetimibe or non-study statin and average change in 
plasma LDL cholesterol from baseline, by period of follow-up
Figure 2: Life-table plot of eﬀ ects of allocation to simvastatin plus ezetimibe versus placebo on major 
atherosclerotic events
Numbers remaining at risk of a ﬁ rst major atherosclerotic event at the beginning of each year are shown for both 
treatment groups.
543210
4620
4650
4204
4271
3849
3939
3469
3546
2566
2655
1269
1265
Years of follow-up
Number at risk
Placebo
Simvastatin 
plus ezetimibe
0
5
10
15
20
25
Pe
op
le
 su
ﬀe
rin
g 
ev
en
ts
 (%
)
Placebo
Simvastatin plus ezetimibe 
Rate reduction 17% (95% CI 6–26%)
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use was 9% (341 of 3735 patients). Hence, the average 
diﬀ erence in the proportion taking simvastatin plus 
ezetimibe or non-study statin was 61% (table 2). As a 
result, the intention-to-treat comparisons assess the 
eﬀ ects of around two-thirds of participants actually taking 
LDL-cholesterol-lowering treatment daily, which yielded 
an average LDL cholesterol diﬀ erence of 0·85 mmol/L 
(SE 0·02; table 2). The average use of simvastatin plus 
ezetimibe or non-study statin did not vary much among 
diﬀ erent types of patient (webappendix p 1), except that 
the average use was lower in patients who were on 
dialysis than in those who were not (54% vs 65%), which, 
taken together with the lower baseline LDL cholesterol 
concentration in patients on dialysis (2·6 vs 2·9 mmol/L), 
yielded a smaller average LDL cholesterol reduction 
(0·60 vs 0·96 mmol/L; webappendix p 1). 
During the scheduled treatment period, there were 
526 (11·3%) ﬁ rst major atherosclerotic events (non-fatal 
myocardial infarction or coronary death, non-
haemorrhagic stroke, or arterial revascularisation) among 
the 4650 participants allocated simvastatin plus ezetimibe 
compared with 619 (13·4%) among the 4620 allocated 
placebo, corresponding to a signiﬁ cant 17% proportional 
reduction (RR 0·83, 95% CI 0·74–0·94; log-rank 
p=0·0021; ﬁ gure 2 and ﬁ gure 3). There was also a 
signiﬁ cant one-sixth reduction in major vascular events 
(ie, major atherosclerotic events plus non-coronary 
cardiac deaths and haemorrhagic strokes: 701 [15·1%] vs 
814 [17·6%]; RR 0·85, 95% CI 0·77–0·94; p=0·0012; 
webappendix p 2), even when the patients initially 
allocated simvastatin alone were excluded (639 [15·2%] vs 
749 [17·9%]; RR 0·84, 0·75–0·93; p=0·001). 
Allocation to simvastatin plus ezetimibe was associated 
with non-signiﬁ cantly fewer ﬁ rst major coronary events 
(213 [4·6%] vs 230 [5·0%]; RR 0·92, 95% CI 0·76–1·11; 
p=0·37), which reﬂ ected non-signiﬁ cantly fewer non-
fatal myocardial infarctions (134 [2·9%] vs 159 [3·4%]; 
RR 0·84, 0·66–1·05; p=0·12; ﬁ gure 3), but no signiﬁ cant 
diﬀ erence in coronary mortality (91 [2·0%] vs 90 [1·9%]; 
RR 1·01, 0·75–1·35; p=0·95). 
Allocation to simvastatin plus ezetimibe produced a 
signiﬁ cant reduction in non-haemorrhagic stroke 
(131 [2·8%] vs 174 [3·8%]; RR 0·75, 95% CI 0·60–0·94; 
p=0·01; ﬁ gure 3), due chieﬂ y to a signiﬁ cant reduction in 
strokes that were deﬁ nitely ischaemic (114 [2·5%] vs 
157 [3·4%]; RR 0·72, 0·57–0·92; p=0·0073). There were 
non-signiﬁ cantly more patients with haemorrhagic 
stroke (45 [1·0%] vs 37 [0·8%]; RR 1·21, 95% CI 0·78–1·86; 
p=0·4; webappendix p 2). There was a signiﬁ cant 
reduction in the risk of any type of stroke (171 [3·7%] vs 
210 [4·5%]; RR 0·81, 95% CI 0·66–0·99; p=0·04).
Allocation to simvastatin plus ezetimibe signiﬁ cantly 
reduced the incidence of any arterial revascularisation 
(284 [6·1%] vs 352 [7·6%]; RR 0·79, 95% CI 0·68–0·93; 
p=0·0036; ﬁ gure 3), with no evidence of statistical 
heterogeneity (χ1²=2·0, p=0·2) between the reductions in 
coronary revascularisations (149 [3·2%] vs 203 [4·4%]; 
RR 0·73, 0·59–0·90), which was statistically signiﬁ -
cant (p=0·0027), and non-coronary revascularisations 
(ie, carotid, aortic or leg, but not haemodialysis access 
procedures), which was not (154 [3·3%] vs 169 [3·7%]; 
RR 0·90, 0·73–1·12; p=0·36). Among coronary 
revascularisation procedures, there was no evidence of 
statistical heterogeneity (χ1²=0·1, p=0·8) between the 
reductions in percutaneous coronary intervention 
procedures (106 [2·3%] vs 148 [3·2%]; RR 0·71, 95% CI 
0·56–0·91; p=0·0063) and coronary artery bypass grafts 
(50 [1·1%] vs 66 [1·4%]; RR 0·75, 0·52–1·09; p=0·13).
SHARP was not expected to have suﬃ  cient statistical 
power to allow reliable estimation of eﬀ ects on major 
Figure 3: Major atherosclerotic events subdivided by type
MI=myocardial infarction. CHD=coronary heart disease.
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Figure 4: Major 
atherosclerotic events by 
baseline characteristics
χ² tests on 1 degree of freedom 
are shown for heterogeneity 
between rate ratios within 
dichotomous categories and 
for trend within other 
categories. BP=blood pressure. 
MDRD=Modiﬁ ed Diet in 
Renal Disease formula.17 
GFR=glomerular ﬁ ltration rate.
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Figure 5: Cause-speciﬁ c and overall mortality 
CHD=coronary heart disease.
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0·95 (0·76–1·17)
1·24 (0·95–1·61)
1·03 (0·74–1·42)
1·04 (0·81–1·34)
1·53 (0·91–2·59)
1·09 (0·98–1·21)
0·91 (0·62–1·33)
1·05 (0·74–1·49)
0·98 (0·76–1·27)
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0·38
0·39
0·83
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0·13
0·87
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Simvastatin
plus ezetimibe
(n=4650)
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(n=4620)
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Placebo better
Cancer incidence Cancer mortality
Simvastatin plus 
ezetimibe (n=4650)
Placebo 
(n=4620)
p value Simvastatin plus 
ezetimibe (n=4650)
Placebo 
(n=4620)
p value
Lip/mouth/pharynx/oesophagus 14 (0·3%) 16 (0·3%) 0·84 9 (0·2%) 8 (0·2%) 1·0
Stomach 11 (0·2%) 14 (0·3%) 0·68 10 (0·2%) 11 (0·2%) 1·0
Large bowel or intestine 53 (1·1%) 35 (0·8%) 0·07 20 (0·4%) 15 (0·3%) 0·51
Pancreas 9 (0·2%) 10 (0·2%) 1·0 7 (0·2%) 10 (0·2%) 0·62
Liver/gallbladder/bile ducts 8 (0·2%) 4 (0·1%) 0·39 4 (0·1%) 4 (0·1%) 1·0
Lung 42 (0·9%) 35 (0·8%) 0·51 32 (0·7%) 22 (0·5%) 0·23
Other respiratory 3 (0·1%) 4 (0·1%) 1·0 2 (0·0%) 3 (0·1%) 1·0
Skin 136 (2·9%) 153 (3·3%) 0·32 4 (0·1%) 4 (0·1%) 1·0
Breast 29 (0·6%) 21 (0·5%) 0·33 1 (0·0%) 1 (0·0%) 1·0
Prostate 39 (0·8%) 52 (1·1%) 0·20 6 (0·1%) 2 (0·0%) 0·27
Kidney* 31 (0·7%) 23 (0·5%) 0·35 5 (0·1%) 1 (0·0%) 0·22
Bladder and urinary tract (not kidney) 26 (0·6%) 32 (0·7%) 0·50 8 (0·2%) 7 (0·2%) 1·0
Genital site 12 (0·3%) 14 (0·3%) 0·84 4 (0·1%) 2 (0·0%) 0·69
Haematological 26 (0·6%) 27 (0·6%) 1·0 6 (0·1%) 14 (0·3%) 0·12
Other known site 9 (0·2%) 12 (0·3%) 0·65 3 (0·1%) 5 (0·1%) 0·72
Unspeciﬁ ed cancer 13 (0·3%) 7 (0·2%) 0·27 11 (0·2%) 5 (0·1%) 0·21
Any incident cancer† 438 (9·4%) 439 (9·5%) 0·89 132 (2·8%) 114 (2·5%) 0·26
For the individual sites, multiple continuity corrected p values are reported; any value that is based on data from more than ﬁ ve patients could have yielded a value less than 
0·05 by chance. Uncorrected p values that are less than the inverse of the number of such tests were therefore corrected by multiplying by the number of such tests to correct 
for this multiplicity of comparisons. In all cases, this yielded p values of 1·0. *Includes two versus one cases and one versus zero deaths due to cancer in a transplanted kidney. 
†Excludes 18 (0·4%) versus 14 (0·3%) deaths from cancers diagnosed before randomisation.
Table 3: Cancer incidence and cancer mortality by site
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atherosclerotic events in particular clinical circumstances, 
so subgroup analyses were planned only as tertiary 
assessments.12 There was not good evidence that the 
proportional eﬀ ects on major atherosclerotic events 
diﬀ ered between patients on dialysis and not (χ1²=1·3, 
p=0·25; ﬁ gure 4), and nor were there trends towards 
smaller proportional reductions in patients not on dialysis 
with lower eGFR (trend χ1²=0·12, p=0·73) or higher urinary 
albumin excretion (trend χ1²=0·38, p=0·54; ﬁ gure 4). 
Conventionally signiﬁ cant trends in the proportional eﬀ ect 
of allocation to simvastatin plus ezetimibe were observed 
for subgroups deﬁ ned by total cholesterol (trend χ1²=9·01, 
p=0·0027) and body-mass index (trend χ1²=4·04, p=0·04). 
After adjustment for the subgroup-speciﬁ c LDL cholesterol 
reductions, the χ1² statistics were reduced but remained 
conventionally signiﬁ cant for total cholesterol (p=0·02; 
webappendix p 3). 
Allocation to simvastatin plus ezetimibe was associated 
with non-signiﬁ cantly fewer cardiac deaths (253 [5·4%] 
vs 272 [5·9%]; RR 0·93, 95% CI 0·78–1·10; p=0·38; 
ﬁ gure 5) and stroke deaths (68 [1·5%] vs 78 [1·7%]; 
RR 0·87, 0·63–1·20, p=0·39), but with similar numbers 
of deaths due to other vascular causes (40 [0·9%] vs 
38 [0·8%]; RR 1·05, 0·67–1·64, p=0·83); overall, there 
were non-signiﬁ cantly fewer deaths due to any vascular 
cause (361 [7·8%] vs 388 [8·4%]; RR 0·93, 0·80–1·07; 
p=0·30; ﬁ gure 5). Simvastatin plus ezetimibe was 
associated with non-signiﬁ cantly more deaths from any 
non-vascular cause (668 [14·4%] vs 612 [13·2%]; RR 1·09, 
95% CI 0·98–1·21, p=0·13), but was not associated with 
a signiﬁ cant excess of deaths from any particular non-
vascular cause considered separately or with excess 
deaths from any unknown cause (113 [2·4%] vs 
115 [2·5%]; RR 0·98, 0·76–1·27, p=0·87). There was no 
signiﬁ cant eﬀ ect on deaths from any cause (1142 [24·6%] 
vs 1115 [24·1%]; RR 1·02, 95% CI 0·94–1·11; p=0·63).
First post-randomisation cancers occurred in 877 (9%) 
patients during the scheduled follow-up period. There was 
no evidence that simvastatin plus ezetimibe increased the 
incidence of cancer (438 [9·4%] vs 439 [9·5%], RR 0·99, 
95% CI 0·87–1·13, p=0·89; table 3) or of increasing hazard 
with length of follow-up (webappendix p 4). There was 
also no signiﬁ cantly increased incidence of, or mortality 
from, cancer at any particular site (table 3). 
Allocation to simvastatin plus ezetimibe did not yield 
signiﬁ cant excesses of creatine kinase concentrations 
of 10–40 times the upper limit of normal (ULN) or 
greater than 40 times the ULN (table 4). There were 
very few cases of myopathy of any severity (deﬁ ned as 
creatine kinase greater than ten times the ULN with 
muscle symptoms: 9 [0·2%] simvastatin plus ezetimibe 
vs 5 [0·1%] placebo) or of more severe cases with 
rhabdomyolysis (deﬁ ned as myopathy with creatine 
kinase greater than 40 times the ULN: 4 [0·1%] vs 
1 [0·0%]). Nor were there signiﬁ cant excesses of 
persistently raised transaminases to greater than three 
times the ULN, hepatitis, or gallstones (with or without 
complications). Among patients allocated simvastatin 
plus ezetimibe, there were fewer cases of pancreatitis 
without gallstones (table 4). 
Among the 6247 patients not on dialysis at 
randomisation, allocation to simvastatin plus ezetimibe 
did not produce signiﬁ cant reductions in any of the 
prespeciﬁ ed measures of renal disease progression: end-
stage renal disease deﬁ ned as commencement of 
maintenance dialysis or transplantation (1057 [33·9%] vs 
1084 [34·6%]; RR 0·97, 95% CI 0·89–1·05, p=0·41); end-
stage renal disease or death (1477 [47·4%] vs 1513 [48·3%]; 
RR 0·97, 0·90–1·04, p=0·34); and end-stage renal disease 
or doubling of baseline creatinine (1190 [38·2%] vs 
1257 [40·2%]; RR 0·93, 0·86–1·01; p=0·09). 
Discussion
The SHARP results show that lowering LDL cholesterol 
with the combination of simvastatin plus ezetimibe 
safely reduces the risk of major atherosclerotic events in 
a wide range of patients with chronic kidney disease. As 
in people without kidney disease, the proportional 
reduction in major atherosclerotic events produced by a 
given absolute reduction in LDL cholesterol is broadly 
similar irrespective of age, sex, diabetes, history of 
Simvastatin plus 
ezetimibe (n=4650)
Placebo 
(n=4620)
p 
value
Muscle pain
Any report 992 (21·3%) 960 (20·8%) 0·53
Study treatment stopped 49 (1·1%) 28 (0·6%) 0·02
Increased creatine kinase*
>5 to ≤10 times ULN 50 (1·1%) 47 (1·0%) 0·86
>10 to ≤40 times ULN 17 (0·4%) 16 (0·3%) 1·00
>40 times ULN 4 (0·1%) 5 (0·1%) 0·99
Persistently increased 
transaminases†
30 (0·6%) 26 (0·6%) 0·71
Hepatitis
Infective 12 (0·3%) 12 (0·3%) 1·00
Non-infective 6 (0·1%) 4 (0·1%) 0·76
No cause identiﬁ ed 3 (0·1%) 3 (0·1%) 1·00
Any hepatitis 21 (0·5%) 18 (0·4%) 0·76
Gallstones
Complicated 85 (1·8%) 76 (1·6%) 0·55
Uncomplicated 21 (0·5%) 30 (0·6%) 0·25
Pancreatitis (without 
gallstones)
12 (0·3%) 27 (0·6%) 0·02
ULN=upper limit of normal. *Myopathy, deﬁ ned as creatine kinase greater than 
ten times the ULN with muscle symptoms, occurred in nine (0·19%) versus ﬁ ve 
(0·11%) patients, of whom eight (0·17%) versus three (0·06%) were taking 
allocated treatment (and not taking any non-study statin) at the time of the 
event (both p=NS); for rhabdomyolysis, deﬁ ned as myopathy with creatine kinase 
greater than 40 times the ULN (and hence included in counts of myopathies), the 
corresponding numbers were four (0·09%) versus one (0·02%) and four (0·09%) 
versus none, again both p=NS. †Consecutive increases of alanine or aspartate 
transaminase greater than three times the ULN.
Table 4: Eﬀ ects of allocation to simvastatin plus ezetimibe on muscle 
and hepatobiliary system
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vascular disease, and presenting lipid proﬁ le. The 
SHARP results are relevant, therefore, to most patients 
with chronic kidney disease (panel).
The eﬀ ects of lowering LDL cholesterol with a statin 
in populations without chronic kidney disease have 
been described by the Cholesterol Treatment Trialists’ 
(CTT) Collaboration, and show that statin therapy 
reduces the risk of myocardial infarction or coronary 
death, stroke, or coronary revascularisation by about a 
ﬁ fth per 1 mmol/L LDL cholesterol reduction.5 In the 
SHARP trial, an average reduction of 0·85 mmol/L 
yielded a signiﬁ cant 17% reduction in major 
atherosclerotic events, which is similar to the eﬀ ects 
seen in the CTT with statin regimens of equivalent LDL-
lowering eﬃ  cacy. The reduction in non-fatal myocardial 
infarction or coronary death (RR 0·92, 95% CI 0·76–1·11) 
in SHARP was not statistically signiﬁ cant, but the trial 
lacked power for separate assessment of components of 
major athero sclerotic events, and the conﬁ dence interval 
is consistent with the results of the CTT meta-analysis.5 
The signiﬁ cant one-quarter reduction in coronary 
revascularisation pro cedures (p=0·0027) in SHARP 
suggests that the reduction in coronary disease reﬂ ects 
a real beneﬁ t. Similarly, the signiﬁ cant one-quarter 
reduction in ischaemic strokes (p=0·0073) is consistent 
with the one-ﬁ fth reduction reported in previous statin 
trials.5 There was no overall reduction in the risk of 
vascular mortality in SHARP, but this ﬁ nding is again 
what would be expected if, as seen in the CTT analyses, 
reduction of LDL cholesterol reduces coronary mortality 
but has little eﬀ ect on other vascular causes of death.5 
Only 181 (24%) of 749 vascular deaths in SHARP were 
regarded as deﬁ nitely attributable to coronary disease, 
so the expected eﬀ ect of treatment on vascular mortality 
was very small and would have needed a much larger 
trial for its detection.
SHARP did not have suﬃ  cient power to assess the 
eﬀ ects on major atherosclerotic events separately in 
dialysis and non-dialysis patients, but there was not good 
statistical evidence that the proportional eﬀ ects in dialysis 
patients diﬀ ered to those seen in patients not on dialysis. 
Moreover, since about a third of the patients who were 
not on dialysis at baseline began dialysis during the trial 
(with about one third of those doing so within the ﬁ rst 
year), the eﬀ ects of simvastatin plus ezetimibe in the 
dialysis subgroup are reinforced by the favourable results 
in the non-dialysis subgroup. It is also important in any 
comparison of the eﬀ ects on vascular outcomes in 
diﬀ erent circumstances to make allowance for any 
diﬀ erences in the achieved absolute LDL cholesterol 
reduction (which meta-analyses suggest is the chief 
determinant of the proportional reduction in 
atherosclerotic events4,5). Lower baseline LDL cholesterol 
concentrations and less average use of LDL-cholesterol-
lowering therapy led to absolute reductions in LDL 
cholesterol that were about a third smaller in those on 
dialysis (0·60 mmol/L) than in those not on dialysis 
(0·96 mmol/L). After weighting for these LDL cholesterol 
reductions, the proportional reductions in major athero-
sclerotic events per 1 mmol/L LDL cholesterol reduction 
were similar: 25% (RR 0·75, 95% CI 0·56–1·00) for 
stage 3; 21% (RR 0·79 95% CI 0·63–0·98) for stage 4; 
24% (RR 0·76, 95% CI 0·48–1·18) for stage 5; and 16% 
(RR 0·84, 95% CI 0·62–1·13) in patients on dialysis, 
respectively, with a test for trend across these four groups 
that was not signiﬁ cant (χ1²=0·23, p=0·63; webappendix 
p 3). The absence of any trend towards larger beneﬁ t in 
patients with less severe renal impairment is also 
consistent with the ﬁ nding that a quarter of cardiac 
deaths were coronary at each stage of chronic kidney 
disease. Taken together, the available data suggest that 
the most appropriate estimate of the reduction in major 
atherosclerotic events, both in patients on dialysis and 
those who are not, is the overall 19% reduction per 
1 mmol/L LDL cholesterol reduction (webappendix p 3). 
Before completion of the SHARP trial, two trials of 
statin regimens in patients on haemodialysis (4D19 and 
AURORA20), and one trial in patients who had undergone 
renal transplantation (ALERT21), had not detected 
signiﬁ cant beneﬁ ts in their primary outcomes. At ﬁ rst 
sight, these ﬁ ndings might appear to be discrepant with 
our results, but the LDL-cholesterol-weighted proportional 
eﬀ ects on particular vascular outcomes in these three 
trials and SHARP were statistically compatible for 
Panel: Research in context
Systematic review
The Cholesterol Treatment Trialists’ collaborative 
meta-analysis of individual participant data from 
26 randomised trials5 has shown that lowering LDL 
cholesterol with a statin regimen reduces the risk of 
myocardial infarction, coronary death, ischaemic stroke, and 
coronary revascularisation procedures by about a ﬁ fth per 
1 mmol/L LDL cholesterol reduction in a wide range of 
people. However, none of the three trials19–21 in patients with 
chronic kidney disease included in that meta-analysis 
reported a signiﬁ cant reduction in its primary vascular disease 
outcome, leading to uncertainty about whether lowering of 
LDL cholesterol is eﬀ ective in renal patients.
Interpretation
The SHARP randomised trial has now shown that lowering 
of LDL cholesterol with simvastatin plus ezetimibe safely 
reduces the risk of major atherosclerotic events in a wide 
range of patients with chronic kidney disease. When the 
SHARP results are compared with those of the previous 
statin trials in renal patients, it appears that the absence of 
signiﬁ cant reductions in earlier trials could have been due 
both to the much smaller number and the much smaller 
proportion of vascular events in their primary outcomes 
that were related to atherosclerosis and, hence, preventable 
by lowering of LDL cholesterol.
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non-fatal myocardial infarction, non-fatal haemorrhagic 
stroke, non-fatal non-haemorrhagic stroke, coronary 
revascular isation (which was not part of the primary 
outcomes of the 4D and AURORA trials), and any 
vascular death (p values non-signiﬁ cant for all 
heterogeneity tests; ﬁ gure 6). Moreover, the eﬀ ects on 
particular vascular outcomes in these four renal trials 
were compatible with those recorded in the trials of statin 
therapy in non-renal populations that were included in 
the CTT meta-analysis.5 Consequently, the failure to 
achieve statistical signiﬁ cance in the previous renal trials 
might derive from both the much smaller number and 
the much smaller proportion of modiﬁ able vascular 
events in their primary outcomes: whereas more than 
Non-fatal MI
4D
ALERT
AURORA
SHARP
Subtotal: four renal trials
23 other trials
All trials
Heterogeneity between renal trials: χ²₃=0·3 (p=0·96)
Diﬀerence between renal and non-renal trials: χ²₁=2·2 (p=0·14)
Non-fatal non−haemorrhagic stroke
4D
ALERT
AURORA
SHARP
Subtotal: four renal trials
23 other trials
All trials
Heterogeneity between renal trials: χ²₃=6·4 (p=0·09)
Diﬀerence between renal and non-renal trials: χ²₁=3·4 (p=0·07)
Non-fatal haemorrhagic stroke
4D
ALERT
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SHARP
Subtotal: three renal trials
23 other trials
All trials
Heterogeneity between renal trials: χ²₂=0·3 (p=0·87)
Diﬀerence between renal and non-renal trials: χ²₁=0·0 (p=0·93)
Coronary revascularisation
4D
ALERT
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Subtotal: four renal trials
23 other trials
All trials
Heterogeneity between renal trials: χ²₃=0·8 (p=0·85)
Diﬀerence between renal and non-renal trials: χ²₁=0·0 (p=0·90)
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4D
ALERT
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SHARP
Subtotal: four renal trials
23 other trials
All trials
Heterogeneity between renal trials: χ²₃=0·9 (p=0·82)
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33 (1·91%)
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3307 (0·97%)
3619 (0·97%)
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902 (2·85%)
3679 (1·05%)
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366 (1·21%)
4386 (1·29%)
4752 (1·29%)
29 (1·67%)
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236 (0·77%)
2052 (0·61%)
2288 (0·62%)
3 (0·17%)
··
6 (0·13%)
17 (0·09%)
26 (0·10%)
136 (0·04%)
162 (0·04%)
72 (4·29%)
60 (1·15%)
70 (1·53%)
203 (1·09%)
405 (1·34%)
6605 (1·99%)
7010 (1·94%)
167 (9·36%)
73 (1·36%)
324 (6·86%)
388 (1·97%)
952 (3·01%)
4230 (1·21%)
5182 (1·36%)
0·83 (0·70–0·98)
0·73 (0·70–0·76)
0·74 (0·70–0·77)
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Figure 6: Eﬀ ects of LDL-lowering therapy on particular vascular outcomes in four trials in patients with chronic kidney disease and 23 trials in other patients 
Data from the Cholesterol Treatment Trialists’ Collaboration.5 χ² tests are shown for heterogeneity between rate ratios for each outcome in the four trials (4D,19 
ALERT,21 AURORA,20 and SHARP) in patients with chronic kidney disease. MI=myocardial infarction. LDL-C=LDL-cholesterol. 
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half the primary outcomes in 4D and AURORA were 
vascular deaths (for which there were small, and non-
signiﬁ cant, beneﬁ ts), about three-quarters in SHARP 
were non-fatal atherosclerotic events (for which there 
were clear beneﬁ ts). 
The previous trials of statin therapy have shown that the 
proportional reduction in risk is chieﬂ y determined by the 
absolute reduction in LDL cholesterol, and that more 
intensive LDL reduction yields further reductions in risk.4,5 
Addition of ezetimibe to a statin reduces LDL cholesterol 
by the equivalent of around three doublings of the statin 
dose.22 It therefore oﬀ ers a potentially useful method of 
increasing beneﬁ ts in high-risk populations in which 
raising the statin dose is not desirable, either because the 
dose is already high or, as in chronic kidney disease, 
because of concerns about drug toxicity. The design of 
SHARP incorporated a three-way randomised comparison 
with a simvastatin-alone group for the ﬁ rst year so that 
adverse eﬀ ects of the addition of ezetimibe to simvastatin 
could be assessed; as reported previously, no serious safety 
concerns emerged during this period.12 A more reliable 
assessment of the safety of the simvastatin plus ezetimibe 
combination is now provided by comparison with placebo 
among all 9270 patients in SHARP during 4·9 years of 
follow-up. There was no evidence of any excess risk of 
persistent increase of hepatic transaminases, of hepatitis, 
of gallstones, or of pancreatitis. Patients with chronic 
kidney disease are at increased risk of statin-induced 
myopathy,8 but in the SHARP trial the excess incidence of 
myopathy was only about two per 10 000 patients per year 
of treatment with simvastatin plus ezetimibe.
While the SHARP trial was in progress some 
investigators had postulated, on the basis of post-hoc 
analyses of the SEAS trial23 of simvastatin plus ezetimibe 
versus placebo in patients with aortic stenosis, that 
ezetimibe might increase the risk of cancer. This 
hypothesis-generating observation was not supported at 
the time by a hypothesis-testing meta-analysis24 of interim 
data for unadjudicated cancers that had occurred by July, 
2008, in SHARP and the IMPROVE-IT trial of simvastatin 
plus ezetimibe versus simvastatin among patients with 
acute coronary syndromes.25 The current results from 
SHARP involve substantially larger numbers of cancers 
than were available for that previous meta-analysis and, 
again, provide no credible evidence of any excess risk of 
cancer or of death from cancer, either overall or at any 
particular site, and no evidence of any trend towards an 
increased risk with longer exposure to study treatment 
(webappendix p 4). Nor was there any evidence of any 
excess risk of death from particular non-vascular causes. 
Overall, therefore, the combination of simvastatin plus 
ezetimibe allowed LDL cholesterol to be lowered 
substantially, but safely, in a group of patients at high risk 
of vascular disease. 
During SHARP, allocation to simvastatin plus 
ezetimibe reduced LDL cholesterol by an average of 
0·85 mmol/L over about 5 years, yielding a reduction of 
17% in major atherosclerotic events, which is equivalent 
to a one-ﬁ fth risk reduction per mmol/L reduction in 
LDL cholesterol. On average, however, only two-thirds of 
the patients allocated simvastatin plus ezetimibe were 
taking an LDL-cholesterol-lowering regimen and so, with 
full compliance, the LDL cholesterol reduction would 
typically have been about 1·3 (ie, 0·85×3/2) mmol/L. 
This calculation implies that patients with chronic kidney 
disease who take simvastatin plus ezetimibe as prescribed 
would typically reduce their risk of major atherosclerotic 
events by about a quarter (ie, 17%×3/2). In SHARP, the 
annual risk of a major atherosclerotic event in both 
patients on dialysis and those who were not exceeded the 
2% threshold that is widely recommended for LDL-
cholesterol-lowering therapy26 and a reduction of one 
quarter in risk in patients similar to those studied would 
correspond to the prevention of 30–40 major 
atherosclerotic events per 1000 patients treated for 
5 years. Moreover, the absolute beneﬁ t would be even 
larger in renal patients with a previous history of coronary 
heart disease, who were excluded from SHARP, but 
whose absolute risk is two-or-three times higher. These 
beneﬁ ts are substantial and suggest that widespread use 
of LDL-cholesterol-lowering therapy in patients with 
chronic kidney disease would result in a worthwhile 
reduction in cardiovascular disease complications in this 
high-risk population. 
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